DEPLOYDatabase

Company

Precision Neuroscience

Precision Neuroscience is a New York-based brain-computer interface company developing the Layer 7 Cortical Interface, a minimally invasive, safely removable…

Founded
2021
HQ
New York, New York, USA
Status
private

The verified answer

As of Sep 2026, DEPLOY verifies Precision Neuroscience: 1 model, 2 deployments across 2 regions, $120.0M raised. 2 sources back the record.

CategoryBiometric wearables

Overview

Precision Neuroscience is a New York-based brain-computer interface company developing the Layer 7 Cortical Interface, a minimally invasive, safely removable BCI with 1,024 electrodes on a thin flexible film. FDA 510(k) clearance granted April 2025 — first full regulatory clearance for a next-generation wireless BCI.

Tested in 37 patients across Mount Sinai, Penn Medicine, WVU Rockefeller Neuroscience Institute, and Beth Israel. Raised $161M total (Series B $41M, Series C $120M).

Verified record

Verified deployments
2 deployments on file
Active incidents
None on file

Valuation of record

DEPLOY VERIFIED
$1.2B (reported, approximate)as of Nov 2024

Priced roundSeries C post-money

See the full valuations ranking →

Key facts

Headquarters

New York, New York, USA

Founded

2021

Status

private

Type

hardware

Data & sources

Press releases

1

Web sources

1

2 sources backing this record.View all →

Current leadership (2)

Founders (1)

See all founders across the registry →

Safety record

No incidents on record for Precision Neuroscience.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operator customers (1)

Recent coverage

Precision Neuroscience in third-party press

Peers

3 peers across 1 segment. Every Precision Neuroscience competitor derived from shared form-factor and application-domain edges.

bci(3)

3 companies in this segment · highly_concentrated (HHI 3365.5523463639224) · leader Blackrock Neurotech at 3565%